Europe Multiomics Market Size, Share & Trends Analysis Report By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Europe Multiomics Market Trends

Single-Cell, Spatial and AI-Enabled Data Integration Reshape Research Workflows

High-throughput sequencing is moving multi-layer biological studies from millions toward billions of reads per experimental program, while single-cell experiments can profile thousands to millions of cells across RNA, DNA, proteins and chromatin features. Researchers increasingly combine 2–5 molecular modalities rather than analyzing isolated datasets, strengthening demand for cloud-native analysis, spatial biology and automated interpretation. Illumina's 2026 Connected Multiomics release followed input from 40 early-access users, illustrating commercialization of unified multiomic analytics.

AI is further shifting analysis from specialist-operated pipelines toward guided workflows. Illumina added AI-assisted workflow suggestions in version 1.1 in February 2026, followed by expanded eQTL/pQTL functionality in version 1.2. Pharmaceutical research is increasingly applying single-cell genomics, transcriptomics, epigenomics, proteomics and metabolomics simultaneously to drug-response characterization, with datasets spanning 5+ molecular layers and thousands of individual cellular observations.

Europe Multiomics Market Drivers

Precision Medicine and Drug Discovery Increase Multi-Layer Molecular Profiling

European biomedical programs increasingly require integrated molecular evidence rather than single-marker measurements. Workflows combining 3–5 omics layers, cohorts containing thousands of samples and sequencing runs producing millions or billions of reads improve target validation and biomarker discovery. Europe nevertheless represented only around 12% of global commercial clinical trials in 2023, versus 22% in 2013, while worldwide trial activity increased 38%, creating pressure to improve research productivity through richer molecular datasets.

Europe Multiomics Market Restraints

High Data Complexity and Infrastructure Requirements Limit Routine Deployment

Multi-layer experiments can generate terabytes of data, thousands of molecular variables and millions of cell-level measurements, requiring high-performance computing, standardized pipelines and specialist bioinformatics personnel. Integrating 4–6 distinct assay classes also compounds batch effects, storage requirements and validation costs. Current research continues to identify labeled-data scarcity, cross-domain generalization and causal inference as major barriers to AI-driven multiomic modeling.

Europe Multiomics Market Opportunities

Cloud Analytics and AI Create Scalable Translational Research Opportunities

Cloud platforms capable of integrating 5+ biological modalities can reduce fragmented analytical workflows while supporting cohorts containing thousands of samples and billions of measurements. Automated systems are also demonstrating greater research scale: one 2025 exploratory multiomics framework analyzed 10 clinical datasets and generated 360 hypotheses, highlighting the potential for AI-supported biomarker discovery and drug-development workflows.

Challenges in Europe Multiomics Market

Standardization Across Heterogeneous Omics Layers Remains Difficult

Combining genomic, RNA, protein, metabolite and epigenetic measurements means harmonizing 5 molecular layers, multiple measurement units and datasets ranging from thousands to millions of observations. Simultaneous multi-omics probing remains technically challenging despite rapid advances in single-cell sequencing, making reproducibility, validation, missing-data management and cross-platform normalization important commercialization barriers.

Europe Multiomics Market Segmentation

The industry is segmented by omics type, application, technology, offering and end user. Within the mandatory quantitative omics dataset, genomics dominates with approximately 29.8% of 2026 revenue, followed by transcriptomics at 19.8%, proteomics at 15.2%, metabolomics at 10.0%, microbiomics at 9.2%, epigenomics at 8.5%, and lipidomics at 7.5%.

By Omics Type

Genomics is the largest subsegment, increasing from USD 298.99 million in 2025 to USD 349.10 million in 2026 and USD 1,205.88 million in 2034, at a 16.76% CAGR. Its 2026 contribution is approximately 29.8%, supported by sequencing-intensive precision medicine and drug-development programs.

Lipidomics is the fastest-growing subsegment at 17.06% CAGR, compared with microbiomics at 16.89% and epigenomics at 16.54%. Lipidomics increases from USD 88.01 million in 2026 to USD 310.30 million by 2034.

By Application

Drug discovery and development remains a core application as integrated datasets combine genomic variants, RNA expression, protein abundance and metabolite signatures. Precision medicine, biomarker identification, clinical diagnostics, agriculture, nutrigenomics, infectious-disease surveillance and systems biology broaden adoption across 8 application categories and multiple research environments.

Demand is increasingly directed toward workflows combining 2 or more molecular layers, particularly in oncology, immunology and therapeutic-response analysis. Biomarker programs may evaluate thousands of genes, proteins and metabolites simultaneously, supporting multi-dimensional patient stratification.

By Technology

Next-generation sequencing is central to genomics and transcriptomics, while mass spectrometry supports proteomic, metabolomic and lipidomic analysis. The technology structure encompasses 6 categories, including NGS, mass spectrometry, microarrays, single-cell analysis, real-time PCR and integration platforms.

Single-cell and integration platforms represent important emerging technologies as experiments move from bulk averages toward measurements across thousands of cells and multiple modalities. Illumina's recent platform development explicitly combines single-cell, spatial and multimodal analysis capabilities.

By Offering

Software and services, instruments and consumables form the 3 offering categories. Software is becoming increasingly strategic because multiomic projects integrate several datasets, potentially billions of reads and thousands of molecular variables within a single analytical environment.

Instruments and consumables remain fundamental to sample preparation, sequencing and mass-spectrometry workflows, while recurring software and cloud requirements expand as laboratories analyze 2–5 omics layers per project.

By End User

Pharmaceutical and biotechnology companies, academic institutions, CROs, hospitals and clinics, and government/public-health agencies constitute 5 end-user groups. Pharmaceutical organizations increasingly apply multiomics across target discovery, validation and translational development.

Academic institutions remain important adopters because individual research programs can incorporate 3–5 molecular modalities and thousands of biological samples, while hospitals and public-health laboratories represent longer-term clinical translation opportunities.

Europe Multiomics Market Counties Outlook

U.K.

The U.K. represents approximately 20.4% of 2026 country revenue, rising from USD 205.68 million in 2025 to USD 238.84 million in 2026 and USD 789.51 million by 2034, at 16.12% CAGR. Genomics research, pharmaceutical discovery and population-scale sequencing underpin national demand.

Germany

Germany leads with approximately 25.0% of 2026 revenue. The country advances from USD 251.93 million in 2025 to USD 292.59 million in 2026 and USD 968.54 million by 2034, registering 16.14% CAGR, supported by biomedical institutes, diagnostics and pharmaceutical R&D.

France

France contributes approximately 15.0% in 2026, with revenue increasing from USD 151.16 million in 2025 to USD 176.27 million in 2026 and USD 602.64 million in 2034. Its 16.61% CAGR reflects expanding genomics, oncology and translational research.

Spain

Spain contributes approximately 8.0%, increasing from USD 80.62 million in 2025 to USD 94.16 million in 2026 and USD 325.91 million by 2034, representing a 16.79% CAGR. Clinical research and precision-medicine programs support adoption.

Italy

Italy accounts for approximately 10.1% of 2026 revenue and records the fastest country CAGR at 17.00%. Revenue progresses from USD 100.77 million in 2025 to USD 117.90 million in 2026 and USD 414.00 million by 2034.

Russia

Russia contributes approximately 10.5%, reaching USD 122.54 million in 2026 from USD 105.71 million in 2025. Revenue is forecast at USD 399.52 million by 2034, representing a 15.92% CAGR.

Nordic

Nordic countries contribute approximately 5.0%, increasing from USD 50.49 million in 2025 to USD 58.52 million in 2026 and USD 190.67 million by 2034, at 15.91% CAGR, supported by population genomics and research infrastructure.

Benelux

Benelux represents approximately 6.1% of 2026 revenue. Revenue rises from USD 61.37 million in 2025 to USD 71.67 million in 2026 and USD 247.90 million in 2034, registering 16.78% CAGR.

Top players in Europe Multiomics Market

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• 10x Genomics, Inc.
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Oxford Nanopore Technologies plc
• Pacific Biosciences
• Standard BioTools Inc.
• Waters Corporation
• BGI Genomics
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation

Top Two Companies

• Illumina, Inc positioning

Illumina maintains strong positioning across high-throughput sequencing, single-cell, spatial and integrated analytics. Its Connected Multiomics platform entered full customer release in January 2026 after engagement with 40 early-access users, followed by AI-assisted capabilities in version 1.1 during February. A defensible Europe-specific multiomics revenue share percentage is not publicly disclosed; assigning an unsupported percentage would therefore be inappropriate.

• Thermo Fisher Scientific Inc.

positioning Thermo Fisher participates across sequencing-related workflows, mass spectrometry, sample preparation, reagents and analytical software, giving it exposure to genomic, proteomic and metabolomic research. Its breadth across instruments and consumables supports laboratories conducting 2–5-layer studies and high-throughput pharmaceutical workflows. A verified Europe-specific multiomics percentage share is not publicly disclosed, so no fabricated company-share estimate is assigned.

Recent Developments in Europe Multiomics Market

• 2026: Illumina released Connected Multiomics, integrating genomic, transcriptomic, proteomic, epigenomic, single-cell and spatial datasets within a cloud-based analytical environment.
• 2026: Illumina introduced version 1.1 with AI-assisted suggestions designed to guide exploratory multiomic workflows.
• 2026: Connected Multiomics version 1.2 expanded functionality with end-to-end eQTL and pQTL workflows and deeper analytical integration.
• 2025: Illumina unveiled roadmap technologies spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR, methylation and multimodal analytics.
• 2025: Research on automated multiomics interpretation demonstrated analysis across 10 clinical datasets and generation of 360 hypotheses, highlighting increasing AI integration into complex biological-data discovery.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Quantitative country and omics-type estimates are anchored to the mandatory supplied datasets, including 8 country groups, 7 omics categories, 2025/2026/2034 revenue observations and corresponding CAGRs. Country shares and omics contributions were calculated directly from supplied 2026 totals; qualitative technology, competitive and development analysis was triangulated against publicly available company disclosures and scientific literature. No unsupported segment revenue, regional revenue or company-share figures were substituted for the mandatory numerical dataset.